MEITHEAL
GenericsMEITHEAL is a generic drug manufacturer focused on Oncology, Infectious Disease, Cardiovascular. Key products include CONTEPO.
MEITHEAL's Key Drugs
MEITHEAL's core commercial portfolio centers on CONTEPO, spanning Oncology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
MEITHEAL's Recent FDA Approvals
MEITHEAL secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
MEITHEAL's Therapeutic Areas
MEITHEAL's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Infectious Disease, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MEITHEAL's Top Competitors
MEITHEAL's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MEITHEAL Pipeline Snapshot
Active clinical trials for MEITHEAL across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CONTEPO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1993-09-28
- Latest
- 2026-06-15
- Applications
- 82